Literature DB >> 11823518

Recombinant canarypox vaccine-elicited CTL specific for dominant and subdominant simian immunodeficiency virus epitopes in rhesus monkeys.

Sampa Santra1, Jörn E Schmitz, Marcelo J Kuroda, Michelle A Lifton, Christine E Nickerson, Carol I Lord, Ranajit Pal, Genoveffa Franchini, Norman L Letvin.   

Abstract

Since virus-specific CTL play a central role in containing HIV replication, a candidate AIDS vaccine should generate virus-specific CTL responses. In this study, the ability of a recombinant canarypox virus expressing SIV Gag-Pol-Env (ALVAC/SIV gag-pol-env) was assessed for its ability to elicit both dominant and subdominant epitope-specific CTL responses in rhesus monkeys. Following a series of five immunizations, memory CTL responses specific for a dominant Gag epitope could be demonstrated in the peripheral blood of vaccinated monkeys. Memory CTL responses to a subdominant Pol epitope were undetectable in these animals. Following challenge with SIVmac251, the experimentally vaccinated animals developed high frequency CTL responses specific for the dominant Gag epitope that emerged in temporal association with the early containment of viral replication. Interestingly, the experimentally vaccinated, but not the control vaccinated animals, developed CTL responses to the subdominant Pol epitope that were detectable only after containment of early viremia. Thus, recombinant canarypox vaccination elicited low frequency, but durable memory CTL populations. The temporal association of the emergence of the dominant epitope-specific response with early viral containment following challenge suggests that this immune response played a role in the accelerated clearing of early viremia in these animals. The later emerging CTL response specific for the subdominant epitope may contribute to the control of viral replication in the setting of chronic infection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11823518     DOI: 10.4049/jimmunol.168.4.1847

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Prior vaccination increases the epitopic breadth of the cytotoxic T-lymphocyte response that evolves in rhesus monkeys following a simian-human immunodeficiency virus infection.

Authors:  Sampa Santra; Dan H Barouch; Marcelo J Kuroda; Jörn E Schmitz; Georgia R Krivulka; Kristin Beaudry; Carol I Lord; Michelle A Lifton; Linda S Wyatt; Bernard Moss; Vanessa M Hirsch; Norman L Letvin
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

2.  Ability of herpes simplex virus vectors to boost immune responses to DNA vectors and to protect against challenge by simian immunodeficiency virus.

Authors:  Amitinder Kaur; Hannah B Sanford; Deirdre Garry; Sabine Lang; Sherry A Klumpp; Daisuke Watanabe; Roderick T Bronson; Jeffrey D Lifson; Margherita Rosati; George N Pavlakis; Barbara K Felber; David M Knipe; Ronald C Desrosiers
Journal:  Virology       Date:  2006-09-07       Impact factor: 3.616

3.  Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels.

Authors:  Ranajit Pal; David Venzon; Sampa Santra; Vaniambadi S Kalyanaraman; David C Montefiori; Lindsey Hocker; Lauren Hudacik; Nicolas Rose; Janos Nacsa; Yvette Edghill-Smith; Marcin Moniuszko; Zdenek Hel; Igor M Belyakov; Jay A Berzofsky; Robyn Washington Parks; Phillip D Markham; Norman L Letvin; Jim Tartaglia; Genoveffa Franchini
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

4.  Comparative vaccine studies in HLA-A2.1-transgenic mice reveal a clustered organization of epitopes presented in hepatitis C virus natural infection.

Authors:  Nourredine Himoudi; Jean-Daniel Abraham; Anne Fournillier; Yu Chun Lone; Aurélie Joubert; Anne Op De Beeck; Delphine Freida; François Lemonnier; Marie Paule Kieny; Geneviève Inchauspé
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

Review 5.  Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV.

Authors:  Monica Vaccari; Poonam Poonam; Genoveffa Franchini
Journal:  Expert Rev Vaccines       Date:  2010-09       Impact factor: 5.217

6.  Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses.

Authors:  Sampa Santra; Dan H Barouch; Birgit Korioth-Schmitz; Carol I Lord; Georgia R Krivulka; Faye Yu; Margaret H Beddall; Darci A Gorgone; Michelle A Lifton; Ayako Miura; Valerie Philippon; Kelledy Manson; Phillip D Markham; John Parrish; Marcelo J Kuroda; Jörn E Schmitz; Rebecca S Gelman; John W Shiver; David C Montefiori; Dennis Panicali; Norman L Letvin
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-16       Impact factor: 11.205

7.  Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120.

Authors:  L Jean Patterson; Nina Malkevitch; Joel Pinczewski; David Venzon; Yuanmei Lou; Bo Peng; Cindy Munch; Melissa Leonard; Ersell Richardson; Kristine Aldrich; V S Kalyanaraman; George N Pavlakis; Marjorie Robert-Guroff
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.